Verapamil Tablets Bp 120mg
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Verapamil 120mg Tablets.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 120 mg of verapamil hydrochloride For excipients, see 6.1.
3. PHARMACEUTICAL FORM
Coated tablets
Biconvex, film-coated tablets engraved 3T1 or 120/0241 and plain on the reverse.
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Verapamil is indicated for the treatment and prophylaxis of angina pectoris. It may be used in the treatment and prophylaxis of paroxysmal supraventricular tachycardia, atrial fibrillation and atrial flutter; (verapamil should not be used where atrial flutter/fibrillation complicates Wolff-Parkinson-White syndrome). Verapamil may also be used in the management of mild to moderate hypertension and renal hypertension.
4.2 Posology and method of administration
Angina Pectoris
Adults: The usual dosage is 120 mg three times daily.
80 mg three times daily may be satisfactory in some patients with angina of effort. Less than 120 mg three times daily is not likely to be effective in angina at rest and variant angina.
Children: No data available.
Supraventricular tachycardia
Adults: 40- 120 mg three times daily according to the severity of the condition.
2 years and above: One to three 40 mg tablets two to three times daily according to age and effectiveness.
Hypertension
Adults: The usual dosage is 160 mg twice a day. However, a minority of patients
may be successfully controlled on 120 mg twice a day while others may require up to 480 mg daily given in divided doses.
Children: Up to 10 mg/kg/day, in divided doses, according to the severity of the
disease.
The Elderly: No specific dosage recommendations, except:
a) In those patients with impaired liver function, particular attention should be paid to dosage because of reduced drug metabolism.
b) In cardiac conduction disturbances, the effects of verapamil and beta-blockers or other cardio-depressive drugs may be additive.
4.3. Contraindications
• Hypersensitivity to the active substance or to any of the excipients.
• Cardiogenic shock;
• Acute myocardial infarction complicated by bradycardia,
• marked hypotension or left ventricular failure;
• hypotension of less than 90 mmHg systolic
• bradycardia (< 50 beats / min),
• uncompensated heart failure,
• second or third degree atrioventricular (AV) block (except in patients with a functioning artificial pacemaker),
• sino-atrial block,
• sick sinus syndrome (except in patients with a functioning artificial pacemaker)
• Concomitant ingestion of grapefruit juice is also contra-indicated.
• Patients with atrial flutter/fibrillation in the presence of an accessory pathway (e.g. Wolff-Parkinson-White (WPW) syndrome) may develop increased conduction across the anomalous pathway and ventricular tachycardia may be precipitated
4.4. Special warnings and precautions for use
Caution should be observed in the acute phase of myocardial infarction.
Verapamil may affect impulse conduction and should be used with caution in patients with bradycardia or first degree atrioventricular block. The effects of verapamil and beta blockers or other drugs with a cardio-depressive action may be additive both with respect to conduction and contraction, therefore care must be exercised when these are administered concurrently or closely together. This is especially true when either drug is administered intravenously.
Patients with atrial fibrillation/flutter in association with an accessory pathway (eg. Wolff-Parkinson-White syndrome) may rarely develop increased conduction across the anomalous pathway and ventricular tachycardia may be precipitated.
If there are signs of tachycardia-induced heart failure (energetic exhaustion of the myocardium) digitalisation is necessary before intravenous administration of verapamil.
Verapamil may affect left ventricular contractility as a result of its mode of action. Although this effect is small and normally not important, cardiac failure may be precipitated or aggravated if it exists. Thus in patients with poor ventricular function, verapamil should only be given after appropriate therapy for cardiac failure, such as digitalis etc.
In patients with impaired liver function, particular attention should be paid to the dosage because of reduced drug metabolism. The disposition of verapamil in patients with renal impairment has not been fully established and careful patient monitoring is recommended. Verapamil is not removed during dialysis.
When treating hypertension with verapamil, monitoring of the patient’s blood pressure at regular intervals is required.
Caution should be exercised in treatment with HMG CoA reductase inhibitors (e.g., simvastatin, atorvastatin or lovastatin) for patients taking verapamil. These patients should be started at the lowest possible dose of verapamil and titrated upwards. If verapamil treatment is to be added to patients already taking an HMG CoA reductase inhibitor (e.g., simvastatin, atorvastatin or lovastatin), refer to advice in the respective statin product information.
Lactose
Verapamil Tablets contains the ingredient, lactose. Patients with rare hereditary problems of fructose intolerance should not take this medicine.
4.5. Interactions with other medicinal products and other forms of interaction
In vitro metabolic studies indicate that verapamil hydrochloride is metabolized by cytochrome P450 CYP3A4, CYP1A2, CYP2C8, CYP2C9 and CYP2C18. Verapamil has been shown to be an inhibitor of CYP3A4 enzymes and P-glycoprotein (P-gp). Clinically significant interactions have been reported with inhibitors of CYP3A4 causing elevation of plasma levels of verapamil hydrochloride while inducers of CYP3A4 have caused a lowering of plasma levels of verapamil hydrochloride, therefore, patients should be monitored for drug interactions. The following are potential drug interactions associated with verapamil:
Acetylsalicylic acid
Concomitant use of verapamil with aspirin may increase the risk of bleeding.
Alcohol
Increase in blood alcohol has been reported.
Alpha blockers
Verapamil may increase the plasma concentrations of prazosin and terazosin which may have an additive hypotensive effect.
Antiarrhythmics
Verapamil may slightly decrease the plasma clearance offlecainide whereas flecainide has no effect on the verapamil plasma clearance.
Verapamil may increase the plasma concentrations of quinidine. Pulmonary oedema may occur in patients with hypertrophic cardiomyopathy
The combination of verapamil and antiarrhythmic agents may lead to additive cardiovascular effects (e.g. AV block, bradycardia, hypotension, heart failure).
With verapamil taken with either disopyramide or flecainide there is an increased risk of myocardial depression and asystole.
Anticonvulsants
Verapamil may increase the plasma concentrations of carbamazepine. This may produce side effects such as diplopia, headache, ataxia or dizziness. Verapamil may also increase the plasma concentrations of phenytoin.
Antidepressants
Verapamil may increase the plasma concentrations of imipramine.
Antidiabetics
Verapamil may increase the plasma concentrations of glibenclamide (glyburide).
Antihypertensives, diuretics, vasodilators
Potentiation of the hypotensive effect.
Anti-infectives
Rifampicin may reduce the plasma concentrations of verapamil which may produce a reduced blood pressure lowering effect. Erythromycin, clarithromycin and telithromycin may increase the plasma concentrations of verapamil.
Antineoplastics
Verapamil may increase the plasma concentrations of doxorubicin.
Barbiturates
Phenobarbital may reduce the plasma concentrations of verapamil.
Benzodiazepines and other anxiolytics
Verapamil may increase the plasma concentrations of buspirone and midazolam.
Beta blockers
Verapamil may increase the plasma concentrations of metoprolol and propranolol which may lead to additive cardiovascular effects (e.g. AV block, bradycardia, hypotension, heart failure).
Intravenous beta-blockers should not be given to patients under treatment with verapamil.
Cardiac glycosides
Verapamil may increase the plasma concentrations of digitoxin and digoxin. Verapamil has been shown to increase the serum concentration of digoxin and caution should be exercised with regard to digitalis toxicity. The digitalis level should be determined and the glycoside dose reduced, if required.
Colchicine
Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (P-gp). Verapamil is known to inhibit CYP3A and P-gp. When verapamil and colchicine are administered together, inhibition of P-gp and/or CYP3A by verapamil may lead to increased exposure to colchicine. Combined use is not recommended.
H2 Receptor antagonists
Cimetidine may increase the plasma concentrations of verapamil.
HIV antiviral agents
Due to the metabolic inhibitory potential of some of the HIV antiviral agents, such as ritonavir, plasma concentrations of verapamil may increase. Caution should be used or dose of verapamil may be decreased.
Immunosuppressants
Verapamil may increase the plasma concentrations of ciclosporin, everolimus, sirolimus and tacrolimus.
Inhaled anaesthetics
When used concomitantly, inhalation anaesthetics and calcium antagonists, such as verapamil hydrochloride, should each be titrated carefully to avoid additive cardiovascular effects (e.g.
AV block, bradycardia, hypotension, heart failure).
Lipid lowering agents
Verapamil may increase the plasma concentrations atorvastatin, lovastatin and simvastatin. Treatment with HMG CoA reductase inhibitors (e.g. simvastatin, atorvastatin or lovastatin) in a patient taking verapamil should be started at the lowest possible dose and titrated upwards. If verapamil treatment is to be added to patients already taking an HMG CoA reductase inhibitor (e.g. simvastatin, atorvastatin or lovastatin), consider a reduction in the statin dose and retitrate against serum cholesterol concentrations.
Atorvastatin has been shown to increase verapamil levels. Although there is no direct in vivo clinical evidence, there is strong potential for verapamil to significantly affect atorvastatin pharmacokinetics in a similar manner to simvastatin or lovastatin. Consider using caution when atorvastatin and verapamil are concomitantly administered.
Fluvastatin, pravastatin and rosuvastatin are not metabolized by CYP3A4 and are less likely to interact with verapamil.
Lithium
Serum levels of lithium may be reduced. However there may be increased sensitivity to lithium causing enhanced neurotoxicity.
Muscle relaxants
Verapamil taken with intravenous dantrolene may cause hypotension, myocardial depression and hyperkalaemia.
Neuromuscular blocking agents employed in anaesthesia The effects may be potentiated.
Serotonin receptor agonists
Verapamil may increase the plasma concentrations of almotriptan.
Theophylline
Verapamil may increase the plasma concentrations of theophylline.
Uricosurics
Sulfinpyrazone may reduce the plasma concentrations of verapamil which may produce a reduced blood pressure lowering effect.
Other
St. John's Wort may reduce the plasma concentrations of verapamil, whereas grapefruit juice may increase the plasma concentrations of verapamil.
4.6 Pregnancy and lactation
Pregnancy
Although there is no published evidence that verapamil has any teratogenic effect, it should not be given during the first trimester of pregnancy, unless in the clinician’s judgement, it is essential for the welfare of the patient. However, verapamil can cause uterine muscle relaxation and this possibility should be considered at term.
Lactation
Verapamil is excreted into the breast milk in small amounts and is unlikely to be harmful. However, hypersensitivity reactions have been reported rarely with verapamil and therefore it should only be used during lactation if in the clinician’s judgement it is essential to the welfare of the patient.
4.7. Effects on ability to drive and use machines
Depending on individual susceptibility, the patient's ability to drive a vehicle, operate machinery or work under hazardous conditions may be impaired. This is particularly true in the initial stages of treatment, when changing over from another drug or when the dose is raised. Like many other common medicines, Verapamil has been shown to increase the blood levels of alcohol and slow its elimination. Therefore, the effect of alcohol may be exaggerated.
4.8 Undesirable effects
Reactions from Postmarketing Surveillance or Phase IV Clinical Trials
The following adverse events reported with verapamil are listed below by system organ class:
Immune system disorders: allergic reactions (e.g. erythema, pruritus, urticaria) are very rarely seen.
Nervous system disorders: headache, dizziness, paraesthesia, tremor and extrapyramidal syndrome.
Ear and labyrinth disorders: vertigo and tinnitus.
Cardiac disorders/vascular disorders: bradycardiac arrhythmias such as sinus bradycardia, sinus arrest with asystole, 2nd and 3rd degree AV block, bradyarrhythmia in atrial fibrillation, peripheral oedema, palpitations, tachycardia, development or aggravation of heart failure and hypotension. There have been rare reports of flushing.
Gastrointestinal disorders: nausea, vomiting, constipation, ileus and abdominal pain/discomfort. Gingival hyperplasia may occur very rarely when the drug is administered over prolonged periods, and is fully reversible when the drug is discontinued.
Skin and subcutaneous tissue disorders: ankle oedema, Quincke's oedema, Steven-Johnson syndrome, erythema multiforme, erythromelalgia, alopecia and purpura.
Musculoskeletal and connective tissue disorders: muscular weakness, myalgia and arthralgia.
Reproductive system and breast disorders: impotence (erectile dysfunction) has been rarely reported and isolated cases of galactorrhoea. On very rare occasions, gynaecomastia has been observed in elderly male patients under long-term verapamil treatment, and is fully reversible in all cases when the drug was discontinued.
General disorders and administration site conditions: fatigue.
Investigations: A reversible impairment of liver function characterized by an increase of transaminase and/or alkaline phosphatase may occur on very rare occasions during verapamil treatment and is most probably a hypersensitivity reaction. Rises in blood prolactin levels have been reported.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9. Overdose
The course of symptoms in verapamil intoxication depends on the amount taken, the point in time at which detoxification measures are taken and myocardial contractility (age-related). The main symptoms are as follows: blood pressure fall (at times to values not detectable), shock symptoms, loss of consciousness, 1st and 2nd degree AV block (frequently as Wenckebach's phenomenon with or without escape rhythms), total AV block with total AV dissociation, escape rhythm, asystole, bradycardia up to high degree AV block and sinus arrest, hyperglycaemia, stupor and metabolic acidosis. Fatalities have occurred as a result of overdose.
The therapeutic measures to be taken depend on the point in time at which verapamil was taken and the type and severity of intoxication symptoms. Verapamil hydrochloride cannot be removed by haemodialysis.
General measures to be taken:
Gastric lavage with the usual precautions, even later than 12 hours after ingestion, if no gastrointestinal motility (peristaltic sounds) is detectable. Where intoxication by verapamil is suspected, extensive elimination measures are indicated, such as induced vomiting, removal of the contents of the stomach and the small intestine under endoscopy, intestinal lavage, laxative, high enemas. The usual intensive resuscitation measures apply, such as extrathoracic heart massage, respiration, defibrillation and/or pacemaker therapy.
Specific measures to be taken:
Elimination of cardiodepressive effects, hypotension or bradycardia. The specific antidote is calcium, e.g. 10-20 ml of a 10% calcium gluconate solution administered intravenously (2.25 -4.5 mmol), repeated if necessary or given as a continuous drip infusion (e.g. 5 mmol/hour).
The following measures may also be necessary:
In case of 2nd or 3rd degree AV block, sinus bradycardia, asystole: atropine, isoprenaline, orciprenaline or pacemaker therapy.
In case of hypotension: dopamine, dobutamine, noradrenaline.
If there are signs of continuing myocardial failure: dopamine, dobutamine, if necessary repeated calcium injections.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
ATC Code: CO8D A01 Phenylalkylamine derivatives
Verapamil, a phenylalkylamine calcium antagonist, has a balanced profile of cardiac and peripheral effects. It lowers heart rate, increases myocardial perfusion and reduces coronary spasm. In a clinical study in patients after myocardial infarction, verapamil reduced total mortality, sudden cardiac death and reinfarction rate.
Verapamil reduces total peripheral resistance and lowers high blood pressure by vasodilation, without reflex tachycardia. Because of its use-dependent action on the voltage-operated calcium channel, the effects of verapamil are more pronounced on high than on normal blood pressure.
As early as day one of treatment, blood pressure falls; the effect is found to persist also in long-term therapy. Verapamil is suitable for the treatment of all types of hypertension: for monotherapy in mild to moderate hypertension; combined with other antihypertensives (in particular with diuretics and, according to more recent findings, with ACE inhibitors) in more severe types of hypertension. In hypertensive diabetic patients with nephropathy, verapamil in combination with ACE inhibitors led to a marked reduction of albuminuria and to an improvement of creatinine clearance.
5.2. Pharmacokinetic properties
Absorption:
More than 90% of an orally-administered dose of verapamil is absorbed. Due to an intensive hepatic first-pass metabolism, the absolute bioavailability is about 22% with a variability of about 10 - 35%. Under multiple dosing, bioavailability increases by about 30%.
Bioavailability is not affected by food consumption.
Distribution, biotransformation and elimination:
Plasma concentrations reach their peak 4 - 8 hours after drug intake. Plasma protein binding of verapamil is about 90%. The elimination half-life is about 5 - 8 hours. The mean residence time of modified-release verapamil is 13 hours. After repeated single daily doses, steady-state conditions are reached between 3 - 4 days.
Within 5 days, approximately 70% of an orally-administered dose is excreted in the urine and about 16% with the faeces. Only 3 - 4 % is eliminated renally as unchanged drug. The drug is extensively metabolized. A number of metabolites are generated in humans (twelve have been identified). Of these metabolites only norverapamil has any appreciable pharmacological effect (approximately 20% that of the parent compound, which was observed in a study with dogs). Norverapamil represents about 6% of the dose eliminated in urine. Norverapamil can reach steady-state plasma concentrations approximately equal to those of verapamil itself. Renal insufficiency does not affect the kinetics of verapamil.
At-risk patients:
In patients with liver cirrhosis, bioavailability is increased and elimination half-life is prolonged. In patients with compensated hepatic insufficiency, no influence on the kinetics of verapamil was observed.
5.3 Preclinical safety data
Preclinical information has not been included because the safety profile of verapamil has been established after many years of clinical use. Please refer to section 4.
6 PHARMACEUTICAL PARTICULARS
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
The tablet contains:
Lactose Monohydrate Maize Starch
Microcrystalline Cellulose (E460)
Sodium Starch Glycolate (Type A) (E576) Povidone (E1201)
Silica Colloidal Anhydrous Magnesium Stearate (E572).
Water, purified
The coating contains: Hypromellose (E464) Polyethylene glycol 400 and 4000 Quinolone yellow (E104) Titanium dioxide (E171)
Iron oxide (E172).
Carnauba Wax: Powder Water, purified
6.2 Incompatibilities
Not applicable.
6.3 Shelf life
48 months.
6.4 Special precautions for storage
Store at or below 25°C.
6.5 Nature and contents of container
Polypropylene or HDPE containers with polyethylene or LDPE lids or child resistant caps in packs of 100 and 250 tablets.
PVdC coated PVC film with hard temper aluminium foil blister strips in packs of 7, 10, 14, 21, 28, 30, 56, 60, 84, 90, 100, 110, 112, 120, 150, 160 and 168 tablets.
Not all pack sizes may be marketed.
6.6 Instructions for use/handling
Not applicable.
7 MARKETING AUTHORISATION HOLDER
TEVA UK Limited
Brampton Road, Hampden Park
Eastbourne, East Sussex, BN22 9AG
8. MARKETING AUTHORISATION NUMBER
PL 00289/0282
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
9.
10
24/11/99
DATE OF REVISION OF THE TEXT
08/07/2015